A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index
Open Access
- 18 October 2005
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 93 (10) , 1098-1105
- https://doi.org/10.1038/sj.bjc.6602836
Abstract
Treatment of non-small-cell lung cancer (NSCLC) might take into account comorbidities as an important variable. The aim of this study was to generate a new simplified comorbidity score (SCS) and to determine whether or not it improves the possibility of predicting prognosis of NSCLC patients. A two-step methodology was used. Step 1: An SCS was developed and its prognostic value was compared with classical prognostic determinants in the outcome of 735 previously untreated NSCLC patients. Step 2: the SCS reliability as a prognostic determinant was tested in a different population of 136 prospectively accrued NSCLC patients with a formal comparison between SCS and the classical Charlson comorbidity index (CCI). Prognosis was analysed using both univariate and multivariate (Cox model) statistics. The SCS summarised the following variables: tobacco consumption, diabetes mellitus and renal insufficiency (respective weightings 7, 5 and 4), respiratory, neoplastic and cardiovascular comorbidities and alcoholism (weighting=1 for each item). In step 1, aside from classical variables such as age, stage of the disease and performance status, SCS was a statistically significant prognostic variable in univariate analyses. In the Cox model weight loss, stage grouping, performance status and SCS were independent determinants of a poor outcome. There was a trend towards statistical significance for age (P=0.08) and leucocytes count (P=0.06). In Step 2, both SCS and well-known prognostic variables were found as significant determinants in univariate analyses. There was a trend towards a negative prognostic effect for CCI. In multivariate analysis, stage grouping, performance status, histology, leucocytes, lymphocytes, lactate dehydrogenase, CYFRA 21-1 and SCS were independent determinants of a poor prognosis. CCI was removed from the Cox model. In conclusion, the SCS, constructed as an independent prognostic factor in a large NSCLC patient population, is validated in another prospective population and appears more informative than the CCI in predicting NSCLC patient outcome.Keywords
This publication has 53 references indexed in Scilit:
- Korreliert der Charlson-Comorbidity-Index mit dem postoperativen Verlauf bei Patienten mit Magenkarzinom?Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie, 2003
- The Impact Of Co-morbid Disease on Cancer Control and Survival Following Radical CystectomyJournal of Urology, 2003
- Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions: Is curative irradiation feasible? Final results of a prospective studyLung Cancer, 2002
- Comorbidity in operable lung cancerLung Cancer, 2002
- Survival analysis 1982–1991: The second decade of the proportional hazards regression modelStatistics in Medicine, 1991
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- A new clinical-anatomic staging system for evaluating prognosis and treatment of prostatic cancerJournal of Chronic Diseases, 1986
- Cancer of the larynx: A new staging system and a re-appraisal of prognosis and treatmentJournal of Chronic Diseases, 1977
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958